ANDA 206411, held by Zydus Lifesciences. Diclofenac Sodium.
As of Nov 16, 2026, ANDA 206411 (Diclofenac Sodium), held by Zydus Lifesciences, was first approved by FDA on Apr 17, 2018, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 17, 2018 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Diclofenac Sodium1.5% · solution;topical | Diclofenac Sodium | Rx |
| Nov 21, 2024 | Supplement 3Labeling · Standard review | Approved | None posted |
| Apr 28, 2021 | Supplement 2Labeling · Standard review | Approved | None posted |
| Apr 17, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters